- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:55 | AstraZeneca/Daiichi Sankyo's Datroway granted FDA approval in breast cancer | ||
| 13:55 | GSK's Jemperli combination approved by EC for expanded endometrial cancer use | ||
| 13:55 | Gilead's Livdelzi approved by MHRA to treat primary biliary cholangitis in adults | ||
| Fr | AstraZeneca's Calquence granted FDA approval in untreated mantle cell lymphoma | ||
| Fr | Amgen's Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer | ||
| Fr | ICR researchers uncover genes responsible for tumour progression in prostate cancer | ||
| Fr | PM Society Awards 2025 - tickets now on sale | ||
| Do | Eli Lilly's Omvoh granted FDA approval to treat Crohn's disease in adults | ||
| Do | Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases | ||
| Do | Santhera's Duchenne muscular dystrophy drug Agamree accepted by SMC | ||
| Mi | AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn | ||
| Mi | Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer's drug | ||
| Mi | Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer | ||
| Di | J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition | ||
| Di | Eli Lilly to acquire Scorpion's solid tumour programme in deal worth $2.5bn | ||
| Di | Boehringer gains access to Synaffix's ADC technology through $1.3bn licensing deal | ||
| 13.01. | Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn | ||
| 13.01. | GSK to expand gastrointestinal cancer pipeline with $1bn IDRx acquisition | ||
| 13.01. | Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma | ||
| 10.01. | Bayer's non-hormonal menopause drug shows promise in phase 3 breast cancer trial | ||
| 10.01. | Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer | ||
| 10.01. | Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies | ||
| 09.01. | AstraZeneca/Merck's Lynparza recommended by NICE to treat advanced breast cancer | ||
| 09.01. | Sanofi and Alloy Therapeutics enter central nervous system deal worth over $427m | ||
| 09.01. | FDA accepts updated protocol for Annovis' phase 3 Alzheimer's disease study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
